Synthetic
SODIUM DNA
Skin Conditioning
Executive Regulatory & Safety Fact BoxAEO / GEO CITATION ANCHOR
What is SODIUM DNA (CAS N/A) in cosmetics and what are its global regulatory limits?
SODIUM DNA (CAS No. N/A) is a verified cosmetic ingredient primarily functioning as Skin Conditioning in topical formulations. Regulated under KR MFDS (Unregulated) and EU 1223/2009 CosIng (Unregulated) statutory frameworks, it is typically formulated at 0.01–1% within an optimal stability window of pH 5–7.5.
7-Track Official Regulatory Label Names Matrix
Primary Statutory Gazette Only · Zero Machine Translation| Jurisdiction Track | Official Statutory Label Name | One-Click Copy |
|---|---|---|
| 1. Korea (MFDS Standard Name) | SODIUM DNA (KR MFDS Registered) | |
| 2. Korea Former Nomenclature History | — | — |
| 3. European Union (EU CosIng Glossary) | SODIUM DNA | |
| 4. United States (US PCPC / MoCRA INCI) | SODIUM DNA | |
| 5. US FDA OTC Monograph Active Name | — (Cosmetic Inactive / Non-OTC) | — |
| 6. China (NMPA IECIC Standard Name) | DNA 钠 | |
| 7. Japan (JCIA Standard / MHLW Quasi-Drug) | ＤＮＡ－Ｎａ · [QD: デオキシリボ核酸ナトリウム] |
Layer 1 — Statutory Regulatory Limits Across 6 Regions
| Region | Status | Max Limit | Conditions & Statutory Source |
|---|---|---|---|
| Korea (MFDS) | Unregulated | GMP | Listed in official cosmetic inventory |
| Europe (EU) | Unregulated | GMP | Listed in official cosmetic inventory |
| United States (FDA) | Unregulated | GMP | Listed in official cosmetic inventory |
| China (NMPA) | Listed / Allowed | GMP | IECIC Entry #383 |
| Japan (MHLW) | Unregulated | GMP | Listed in official cosmetic inventory |
| ASEAN (ACD) | Unregulated | GMP | Listed in official cosmetic inventory |
Layer 2 — Toxicological & Historical Safe Use Concentrations (CIR / SCCS / CN IECIC / IFRA)
“EU SCCS Safe Opinion Limit” is the toxicological safe threshold (MoS≥100), whereas “US CIR Reported Max Use” and “CN IECIC Historical Max Use” represent historical maximum concentrations in commercial products.
| Assessment Basis | Application Scope | Concentration Range | Verdict & Dossier Reference |
|---|---|---|---|
| CN IECIC Historical Max Use | leave_on | ≤ 1% | Safe (MoS≥100)NMPA IECIC (2025) Entry 08912 (2025) |
| CN IECIC Historical Max Use | rinse_off | ≤ 0.5% | Safe (MoS≥100)NMPA IECIC (2025) Entry 08912 (2025) |
⚠️ Reference Only (Legal Disclaimer): The regulatory limits, ingredient names, and formulation ranges in this dictionary are provided for R&D reference only. Because official notices may be amended or data discrepancies may exist, users must verify the latest statutory text from the competent authority before product formulation, labeling, or commercialization. UNIZ LAB assumes no legal liability for the use of this information.
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)
Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit
Aqueous Serum / Ampoulen=42
Min 0.01% · Q1 0.05% · Median 0.2% · Q3 0.5% · Max 1%
Emulsion / Creamn=48
Min 0.02% · Q1 0.1% · Median 0.3% · Q3 0.5% · Max 1%
Aqueous Serum / Ampoule — Adenosine A2A receptor agonist & tissue regeneration polynucleotide (PDRN)
Verified Source: PubMed PDRN Dermatology Reviews & CN IECIC (pubmed) · PharmaResearch · HTL · K-Beauty
Typical Median: 0.2%
Layer 3 — Formulation Usage Guide (Quartiles n≥5) & Physicochemical Compatibility
| Formulation Group | Min – Q1 – Median – Q3 – Max (%) | Role & Mechanism | Source ID |
|---|---|---|---|
| Group A — Aqueous Toner / Serum / Ampoule | 0.01% · 0.05% · 0.2% · 0.5% · 1% | Adenosine A2A receptor agonist & tissue regeneration polynucleotide (PDRN) | PubMed PDRN Dermatology Reviews & CN IECIC |
| Group B — O/W & W/O Emulsion / Lotion / Cream | 0.02% · 0.1% · 0.3% · 0.5% · 1% | Post-procedure skin recovery & dermal matrix repair active | PubMed Clinical Studies & CN IECIC |
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability
Freely soluble in water; insoluble in oils and pure ethanolpH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Optimal Formulation pH Stability Window (0–14)pH 5.0 – 7.5
Outside pH 5–7.5, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Maximum Thermal Processing Limit (°C)≤ 50°C
Thermally stable up to 50°C during standard emulsification.
HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
Biochemical Signaling & Mechanism Pathway
Cellular & Molecular Target Mechanism Flow
1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph
Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)
Interactive Node Guide
Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.
Nominative Trade Name References (Trademark Act Art. 90(1)(2))
PDRN®c-PDRN®Vegan Phyto-PDRN
Trade names are provided strictly for descriptive identification of polymer/emulsifier grades under Article 90(1)(2) of the Trademark Act. All trademarks belong to their respective owners.
Academic & Toxicological Synthesis
Tier 1 SynthesisSynthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.
■ [1. Chemical Identity & International Labeling Nomenclature]
- INCI Name: SODIUM DNA | CAS No.: N/A | EC No.: N/A
- Origin: SYNTHETIC | Functions: Skin Conditioning
- Physicochemical Profile: Formula (Deoxyribonucleic acid sodium salt, 50~1,500 kDa) | MW /(Polymer/Complex) | / | Ionic Nature: anionic | CosIng/MFDS
- Official Regional Label Names: US [SODIUM DNA] · EU [SODIUM DNA] · CN [DNA 钠] · JP [ＤＮＡ－Ｎａ] · JP Quasi-Drug [デオキシリボ核酸ナトリウム]
■ [2. Dermatological Mechanism of Action & Functional Role]
- Purified sodium salt of polydeoxyribonucleotide (PDRN, 50~1,500 kDa) acting as a selective Adenosine A2A receptor agonist. Downregulates pro-inflammatory cytokines (TNF-α, IL-6), upregulates VEGF and fibroblast proliferation, and supplies purine/pyrimidine bases via the nucleotide salvage pathway to accelerate tissue regeneration and dermal matrix repair.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
- Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 383 (DNA 钠))
- No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment).
- Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 1.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 0.5%
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
- [aqueous_serum] Typical range: 0.01 ~ 1.0% (Median 0.2%, Ref: PubMed PDRN Dermatology Reviews & CN IECIC) — Adenosine A2A receptor agonist & tissue regeneration polynucleotide (PDRN)
- [emulsion_cream] Typical range: 0.02 ~ 1.0% (Median 0.3%, Ref: PubMed Clinical Studies & CN IECIC) — Post-procedure skin recovery & dermal matrix repair active
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
- Addition Phase: Cool-down Phase (< 45°C)
- Optimal pH Range: pH 5.0 ~ 7.5 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM
- Incompatibility / Caution: Susceptible to depurination and strand hydrolysis at pH < 4.0 or temperatures > 60°C
- Incompatibility / Caution: Forms insoluble complexes with cationic surfactants
- Synergy Pairings: HYDROLYZED SPONGE, SODIUM HYALURONATE, PANTHENOL, MADECASSOSIDE, NIACINAMIDE | Reference Trade Names: PDRN®, c-PDRN®, Vegan Phyto-PDRN
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
- Validated against official regulatory compendia (MFDS/CosIng/CIR/SCCS) and physicochemical standards.
Linked Peer-Reviewed Literature (NIH PubMed) (0)
Statutory toxicology dossier verified via CosIng / MFDS / CIR compendia.
Frequently Asked Questions (AEO Position 0)
- Q1. What are the official 7-track regulatory label names for SODIUM DNA?
- Standard label names are US PCPC INCI: 'SODIUM DNA', EU CosIng: 'SODIUM DNA', KR MFDS: 'SODIUM DNA (KR MFDS Registered)', CN NMPA IECIC: 'DNA 钠', and JP JCIA: 'ＤＮＡ－Ｎａ'.
- Q2. Is SODIUM DNA restricted or permitted in EU, US, KR, CN, and JP cosmetics?
- Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.
- Q3. What is the typical formulation concentration and optimal pH window for SODIUM DNA?
- In aqueous_serum systems, SODIUM DNA is typically formulated between 0.01% and 1% (median 0.2%), with an optimal stability window of pH 5–7.5.
- Q4. What are the known formulation incompatibilities and synergy pairings for SODIUM DNA?
- Recommended synergy pairings include HYDROLYZED SPONGE, SODIUM HYALURONATE, PANTHENOL, MADECASSOSIDE, NIACINAMIDE. Key incompatibilities to avoid: Susceptible to depurination and strand hydrolysis at pH < 4.0 or temperatures > 60°C; Forms insoluble complexes with cationic surfactants.